MS breakthrough? trial tests if older patients can ditch heavy drugs

NCT ID NCT07189325

Not yet recruiting Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study looks at whether people with relapsing-remitting multiple sclerosis (MS) who are over 40 and have been stable on strong anti-CD20 drugs for at least 3 years can safely switch to a milder therapy without their disease coming back. Half the participants will stay on their current anti-CD20 treatment, while the other half will switch to a less powerful drug. The goal is to see if the switch is just as good at preventing relapses and new brain lesions, potentially reducing side effects and treatment burden.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Neurology Department, Hospital Gui de Chauliac

Montpellier, 34295, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANTI-CD20 THERAPY ANTI-CD20 THERAPY RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS)